gastroparesi clinic evalu drug treatment guidanc industri draft guidanc guidanc document distribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpswwwregulationsgov submit written comment docket manag staff hfa 305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact maureen dewey 301 7960845 us depart health human servic food drug administr center drug evalu research cder august 2019 clinicalmed revis 1 gastroparesi clinic evalu drug treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguid complianc regulatori informationguid drug us depart heal th human servic food drug administr center drug evalu research cder august 2019 clinicalmed revis 1 tabl content introduct 1 ii background 2 iii endpoint trial design gastroparesi clinic trial 3 trial design 3 b trial popul 4 c approach outcom assess measur 5 trial endpoint 6 1 primari endpoint 6 2 secondaryoth endpoint 6 3 defin clinic meaning within patient chang sign symptom score 6 e statist consider 7 ref erenc 9 contain nonbind recommend draft implement 1 gastroparesi 1 clinic evalu drug treatment 2 guidanc industry1 3 4 5 6 7 draft guidanc final repres current think food drug 8 administr fda agenc topic establish right person 9 bind fda public use altern approach satisfi requir 10 applic statut regul discuss altern approach contact fda staff respons 11 guidanc list titl page 12 13 14 15 16 introduct 17 18 purpos guidanc assist sponsor clinic develop drug 19 treat idiopath diabet gastroparesis2 specif guidanc address fda 20 current recommend regard clinic trial design clinic endpoint assess 21 support develop gastroparesi drug 22 23 draft guidanc intend serv focu continu discuss among 24 respons fda divis offic new drug pharmaceut sponsor academ 25 commun public3 26 27 guidanc revis draft guidanc industri name issu juli 2015 28 chang previou draft reflect fda current think develop clinic 29 outcom assess tool statist consider use tool assess primari 30 secondari efficaci endpoint 31 32 guidanc address detai led patient report outcom pro instrument 33 develop valid topic address guidanc ndustri patient 34 1 guidanc prepar divis gastroenterolog inborn error product center drug evalu research food drug administr 2 purpos guidanc refer drug includ h uman drug therapeut biolog product unless otherwis specifi 3 addit consult guidanc sponsor encourag contact divis discuss specif issu aris develop drug treat gastroparesi contain nonbind recommend draft implement 2 report outcom measur use medic product develop support label claim 35 decemb 2009 4 36 37 detail regard statist analysi clinic trial design address ich 38 guidanc industri e9 statist principl clinic trial septemb 1998 e10 39 choic control group relat issu clinic trial may 2001 respect 40 41 gener fda guidanc document establish legal enforc respons 42 instead guidanc describ agenc current think topic view 43 recommend unless specif regulatori statutori requirem ent cite use 44 word agenc guidanc mean someth suggest recommend 45 requir 46 47 48 ii background 49 50 gastroparesi disord character delay gastric empti dge absenc 51 mechan bstruction symptom chronic episod exacerb parkman et al 52 2004 idiopath form disord account greatest number case 53 karamanoli et al 2007 predominantli affect young adult femal gastroparesi also 54 frequent associ diabet diabet gastroparesi like occur 55 impair neural control gastric motil parkman et al 2004 addit acut 56 hyperglycemia potenti slow gastric empti decreas effect prokinet 57 drug camilleri 2010 58 59 core sign symptom gastroparesi nausea 92 96 percent vomit 68 88 60 percent postprandi full 54 77 percent earli satieti 42 86 percent upper 61 abdomin pai n 36 85 percent hoogerwerf et al 1999 anaparthi et al 2009 patient may 62 experi combin sign symptom vari degre sever pain 63 preval patient idiopath gastroparesi patient diabet 64 gastroparesi patient diabet gastroparesi may experi derang 65 glucos control unpredict gastric empti alter absorpt oral 66 administ hypoglycem drug 67 68 sign symptom gastroparesi overlap gastrointestin condit 69 gastroparesi may incorrectli diagnos bowel obstruct function dyspepsia irrit 70 bowel syndrom peptic ulcer diseas patient sign symptom sugg tive 71 gastroparesi find dge absenc obstruct altern diagnosi provid 72 critic support diagnosi gastroparesi assess use either gastric 73 empti scintigraphi gastric e mpti breath est smartpil motil test system 74 75 urgent medic need develop safe effect therapi treat patient 76 gastroparesi 77 78 4 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document contain nonbind recommend draft implement 3 iii endpoint rial design gastroparesi clinic 79 trial 80 81 primari efficaci assessmen ts adequ well control trial must well defin 82 reliable5 gastroparesi symptomat condit welldefin reliabl pro 83 instru ment easur clin ical import ign sy mptom gastroparesi would 84 ideal p rimari efficaci ass sment tool clinic trial use support label claim 85 treat gastroparesi 6 howev current awar measur 86 appropri pro instru ment gastroparesi becom avail abl ponsor consid 87 strategi discuss follow section design gastroparesi clinic tri al 88 sponsor may also wish review fda center drug evalu research clinic 89 outcom assess coa drug develop tool qualif program web page 90 inform qualifi tool tool current develop 91 92 sponsor may wish includ evalu well defin pro instrument assess relev 93 import sign symptom earli drug develop evalu result 94 doserang phase 2 trial stand alon nonintervent studi support futur use 95 phase 3 trial encourag earli regular discuss fda regard 96 develop pro instrument 97 98 gastroparesi manifest one core sign symptom effect new drug 99 intend treat gastroparesi core sign symptom assess earli p hase 100 trial shoul help inform core sign andor symptom includ 101 prespecifi endpoint intend support label claim base sign symptom 102 treatment like improv import show even drug intend treat 103 subset core sign symptom base mechan drug worsen 104 remain sign symptom gastroparesi exampl drug may expect improv 105 gastroparesi relat nausea vomit abdomin pain base mechan 106 action scenario clinic studi demonstr nausea vomit improv 107 treatment worsen symptom abdomin pain postprandi full 108 earli satieti 109 110 follow section provid recommend regard trial design trial popul 111 outcom ssessment measur trial endpoint statist consider 112 113 trial design 114 115 gener trial design consist rando mize doubl blind placeb ocontr oll trial 116 hould includ 1 2week screen period screen period use 117 investig establish presenc persist tri alentri criteria patient 118 gain experi complet pro instrument employ trial demonstr adequ 119 5 21 cfr 314126 6 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend draft implement 4 understand complianc complet instrument screen period 120 assess gastroparesi sign symptom serv baselin valu use 121 analys primari endpoint see section iii trial endpoint fda recommend 122 baselin assess period least 7 day primari endpoint measur chang 123 sign symptom baselin treatment period least 12 week durat 124 125 trial design address need mainten treat ment prevent recurr ign 126 symptom 127 128 endpoint assess base patient daili report avoid recal error 129 protocol state whether rescu medic ie protocol specifi therapi continu 130 exacerb symptom standard across studi site allow daili diari 131 collect throughout entir trial 132 133 addit recommend random control long term safeti studi 12 month 134 durat appropri prespecifi provis rescu medic hould 135 conduct submit new drug applic 136 137 b trial popul 138 139 idiopath diabet gastroparesi pa tient studi separ clinic trial 140 gener diabet gastroparesi patient experi core sign symptom patient 141 idiopath gastroparesi individu sign symptom may occur often 142 greater sever one popul compar degre diabet control 143 also confound result fulli describ safeti efficaci p opul recommend 144 separ trial idiopath diabet gastroparesi close relat condit 145 singl phase 3 trial popul demonstrat ion reliabl clinic meaning 146 result may support approv indic 7 147 148 recom mend trial entri crite ria includ follow 149 150 trial popul clinic diagnosi idiopath diabet 151 gastroparesi individu trial base document histori gastroparesi 152 symptom exclus potenti etiolog dge abel et al 2008 153 parkman et al 2004 optim abil demonstr treatment effect 154 trial enrol patient higher symptom sever moder sever 155 current accept definit gast roparesi sever 156 sponsor provid justif sever index select includ 157 defin moder sever symptom 158 159 diabet gastroparesi patient control stabl blood glucos level 160 patient prone acut hyperglycem event may confound interpret 161 therapeut effect drug 162 163 7 see guidanc industri provid clinic evid effect human drug biolog product may 1998 contain nonbind recommend draft implement 5 patient opioid exclud pioid use may affect gastrointestin 164 motil potenti confound result 165 166 c approach utcom assess measur 167 168 well defin reliabl pro instrument measur clinic import sign 169 symptom gastroparesi avail recommend five core sign 170 symptom gastroparesi nausea vomit postprandi full earli satieti 171 abdomin pain includ endpoint well control clinic trial karamanoli et al 172 2007 hoogerwerf et al 1999 anaparthi et al 2009 ponsor identifi empir 173 justifi questionnair item word use assess sign symptom 174 gastroparesi includ trial8 175 176 sponsor propos primari endpoint definit see section iii trial endpoint 177 method measur five sign symptom describ pilot 178 propos instrument phase 2 trial provid opportun evalu abil f 179 instrument detect chang provid guidelin interpret clinic meaning 180 within patient chang confirm endpoint definit pilot result inform plan 181 implement propos instrument phase 3 trial word 182 questionnair care thought question request overlap 183 measur concept eg postprandi full earli satieti concept 184 welldefin interpret consist way patient ie questionnair 185 includ definit postprandi full earli satieti term may vari 186 interpret among patient e ach core sign symptom separ measur 187 document clinic trial 188 189 sponsor also specifi mode data collect use patient 190 record daili sign symptom eg electron diari 191 192 sign symptom except vomit rate sever exampl question 193 request item respons rang 0 symptom 4 ost sever symptom 194 0none 1mild 2moder 3sever 4veri sever numer rate scale 195 0 10 0 reflect absenc symptom 10 reflect worst possibl 196 symptom experi possibl rate scale consist across core ign 197 symptom recommend report vomit daili symptom diari 198 measur frequenc rather sever frequenc report exact number 199 time 24 hour period clear definit consid one time 200 vomit provid patient ensur consist within patient 201 report number time vomit occur sever nausea postprandi 202 full earli satieti abdomin pain record base patient worst 203 experi 24 hour period 204 205 8 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend draft implement 6 tria l endpoint 206 207 1 primari endpoint 208 209 chang patient report sign symptom score form basi primari 210 efficaci assess therapeut trial idiopath diabet gastroparesi primari 211 endpoint base pati nt core sign symptom subset gastric 212 empti time use primari efficaci endpoint chang gastric 213 empti time associ chang cli nical import ign 214 symptom patient gastroparesi 215 216 primari endpoint measur chang sign symptom baselin 217 analysi plan includ evalu treatment effect throughout 12 week studi 218 period 219 220 recommend use endpoint base core sign symptom may 221 base pre specifi core sign symptom symptom sever summari score 222 exclud vomit vomit frequenc collect continu variabl primari 223 endpoint limit singl sign symptom sponsor propos summari 224 score evalu question level request level respons determin whether 225 individu question request overli influenc total score current 226 evid recommend one approach score base sever 227 analyz separ base frequenc eg vomit 228 229 2 secondari endpoint 230 231 fda recommend chang baselin individu sign symptom 232 assess part primari endpoint measur secondari endpoint therefor 233 primari secondari endpoint includ evalu five core sign 234 sympt om chang g astric empti time measur secondari endpoint desir 235 abel et al 2008 prespecifi plan address analysi remain core sign 236 symptom includ primari endpoint 237 238 3 defin clinic meaning within patient chang sign symptom 239 score 240 241 aid interpret result ponsor determin amount chang 242 meaning patient total summari score individu sign symptom score 243 ideal base actual data establish advanc phase 3 trial 244 clinic meaning within patient chang threshold may prespecifi two 245 clinic meaning chang threshold interest one clinic import improv 246 baselin one clinic import deterior baselin depend 247 propos mechan action drug trial object propos threshold spe cifi 248 level improv n five core sign symptom spe cifi 249 level improv n subset core sign symptom worsen core sign 250 contain nonbind recommend draft implement 7 symptom would inconsist expect clinic benefit taken account 251 evalu benefit risk 252 253 recommend use anchor base approach typic use phase 2 trial data 254 estim clinic meaning chang approach recommend includ phase 2 255 3 trial multipl anchor scale patient global impress sever pgi 256 patient global impress chang pgic scale intent provid accumul 257 evid help interpret clinic meaningfu l within patient score chang contrast 258 pgic scale pgi scale subject recal error also use assess chang 259 baselin data pgi scale prefer anchor scale pgic scale howev 260 perf ct anchor scale help includ multipl anchor scale anchor base 261 analys 262 263 follow item could ask patient follow assess schedul 264 recal period prespecifi endpoint baselin exampl pgi scale 265 266 pleas choos respons best describ sever gastroparesi 267 symptom insert appropri recal period 268 269 sponsor consid follow respons option item 0none 1mild 270 2moder 3 sever 4 ever 271 272 follow item could ask weekli patient exampl pgic scale 273 274 pleas choos respons best describ overal chang 275 gastroparesi symptom sinc st art take studi medic 276 277 sponsor consid follow respons option item much better littl better 278 chang littl w ors uch w ors 279 280 sponsor determin clinic meaning within patient chang threshold rang use 281 anchor base method eg patient global impress scale anchor supplement 282 empir cumul distribut function ecdf within patient score chang separ 283 ecdf curv gener meaning anchor categori eg improv 284 chang worsen use data pool across trial arm 285 286 e statist consider 287 288 evalu daili diari assess creat trial adequ number 289 assess avail sponsor determin number base evid 290 deriv particular pro assess use trial exampl weekli summari 291 score use gener sponsor provid assess fro least 4 7 day 292 howev evid particular pro assess may support need data 293 higher number day instrument provid r eliabl result 294 295 contain nonbind recommend draft implement 8 efficaci analysi plan clearli defin patient take rescu medic 296 consid final analysi sponsor also propos met hod handl miss 297 data includ miss rescu medic data miss pro dat question request 298 instrument level analysi plan sponsor consid iffer approach 299 trial initi properti approach evalu 300 301 recommend sponsor analyz prim ari secondari endpoint continu 302 ordin variabl recommend use percent age chang gener tradit 303 respond analysi would appropri unl target respons complet resolut 304 sign symptom addit w e encourag use baselin valu 305 covari improv effici primari secondari endpoint analys 306 307 addit sponsor submit support descript analys ie graph ecdf 308 within patient chang baselin primari secondari endpoint treatment arm 309 fda review 310 contain nonbind recommend draft implement 9 ref erenc 311 312 abel tl rk bernstein cutt g farrugia j forster wl hasler rw mcc allum kw olden 313 hp parkman cr parrish pj pasricha cm prather ee soffer r twillman ai vi nik 2006 314 treatment gastroparesi multidisciplinari clinic review neurogastroenterol motil 315 18263283 316 317 abel tl camilleri k donoho wl hasler hc lin ah nauer rw mccallum nowak 318 ml nusynowitz hp parkman p shreve la szarka wj snape ha zi essman 2008 319 consensu recommend gastric empti scintigraphi joint report 320 american neurogastroenterolog motil societi societi nuclear medicin 321 j gastroenterol 103753 763 322 323 anaparthi r n pehlivanov j gradi h yimei pj pasricha 2009 gastroparesi 324 gastroparesi like yndrome respons herapi ts predictor dig di sci 325 5451003 1010 326 327 hoogerwerf wa pj pasricha kalloo mm schuster 1999 pain verlook 328 symptom g astroparesi j gastroenterol 9410291033 329 330 karamanoli g p caenepeel j art j tack 2007 determin ymptom p attern 331 idiopath ever elay g astric empti gastric e mpti r ate p roxim tomach 332 dysfunct gut 5629 36 333 334 parkman hp wl hasler rs fisher 2004 american gastroenterolog associ 335 technic review diagnosi treatment gastroparesi gastroenterolog 336 1275 1592 1622 337 338 parkman hp k yate wl hasler l nguyen pj pasricha wj snape g farrugia kl koch j 339 call tl abel rw mccallum l lee unalp arida j tonascia f hamilton 2011 340 similar differ b etween iabet diopath gastroparesi clin gastroenterol 341 hepatol 910561064 342 16856dftdocx 120922